Filter Releases
 
News Releases
Date Title and Summary View
May 31, 2017
SAN DIEGO, May 31, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology biotechnology company, will present at the 2017 Jefferies Global Healthcare Conference in New York on Wednesday, June 7th at 3:30 p.m. ET/ 12:30 p.m. PT. Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer will presen...
May 4, 2017
SAN DIEGO, May 4, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage oncology biotechnology company, reported financial results for the first quarter 2017 and provided an update on its product development programs. "As anticipated, 2017 will be an important and defining year for Mirati. Our single agent precision...
Mar 9, 2017
SAN DIEGO, March 9, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) ("the Company," "we," "our," "us," or "Mirati") today reported financial results for the fourth quarter and year ended December 31, 2016 and provided an update on its product development programs. "We have made significant progress which positions us to report...
Feb 13, 2017
SAN DIEGO, Feb. 13, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Charles M. Baum, M.D, Ph.D., President and CEO of Mirati, will provide a corporate overview during a fireside chat presentation at the Leerink Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017 at 2:30 p.m. ET (1130am ...
Jan 11, 2017
SAN DIEGO, Jan. 11, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the closing of its previously announced underwritten public offering of 5,002,702 shares of its common stock at a public offering price of $5.60 per share. This includes the exercise in full by the underwriter of its option to purchase up to 652,526 ad...
Jan 6, 2017
SAN DIEGO, Jan. 6, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the pricing of an underwritten public offering of 4,350,176 shares of its common stock at a price to the public of $5.60 per share. In addition, and in lieu of common stock, Mirati is offering to funds affiliated with Boxer Capital, LLC pre-funded warra...
Jan 5, 2017
SAN DIEGO, Jan. 5, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (Mirati or the Company) (NASDAQ: MRTX) today announced data from two ongoing clinical programs, including the Phase 1b and Phase 2 trials of glesatinib, a spectrum selective kinase inhibitor for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of ...
Jan 5, 2017
SAN DIEGO, Jan. 5, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock. Mirati expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offer...
Nov 3, 2016
SAN DIEGO, Nov. 3, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) ("the Company" or "Mirati") today reported financial results for the third quarter ended September 30, 2016 and provided an update on its product development programs. "We are pleased by the continued progress in all three of our clinical development programs d...
Oct 4, 2016
SAN DIEGO, Oct. 4, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the appointment of Chris LeMasters to the newly created position of Executive Vice President and Chief Business Officer, effective September 30, 2016. "Chris' extensive experience in successfully driving corporate development and strategy at ...
Sep 29, 2016
SAN DIEGO, Sept. 29, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the appointment of Dr. Bruce L.A. Carter to the Company's Board of Directors where he will also serve as a member of the Audit Committee and Compensation Committee, effective immediately. "It is a privilege to welcome such a respected and accom...
Aug 4, 2016
SAN DIEGO, Aug. 4, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) (the Company or Mirati) today reported financial results for the second quarter ended June 30, 2016 and provided an update on its product development programs. "We reported progress across our pipeline during the second quarter, including clinical responses...
Jun 22, 2016
SAN DIEGO, June 22, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Mark Gergen will step down as Executive Vice President and Chief Operations Officer to pursue other opportunities, transitioning over the coming months.       "We want to thank Mark for his important contributions and leadership over the p...
Jun 5, 2016
SAN DIEGO, June 5, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today provided an update on three current ongoing clinical programs in patients with non-small cell lung cancer (NSCLC) and other solid tumors. "We are making significant progress in the development of our pipeline as our ongoing clinical programs are showing m...
Jun 1, 2016
SAN DIEGO, June 1, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Charles M. Baum, M.D., Ph.D., President and CEO of Mirati, will present a corporate overview at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 at 11:00 a.m. ET (8:00 a.m. PT) in New York. A live audio webcast of the pres...
May 19, 2016
SAN DIEGO, May 19, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that abstracts on its investigational tyrosine kinase inhibitor candidates, glesatinib (MGCD265) and sitravatinib (MGCD516), will be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago, IL from June 3-...
May 5, 2016
SAN DIEGO, May 5, 2016 /PRNewswire/ --Mirati Therapeutics, Inc. (NASDAQ: MRTX) today reported financial results for the first quarter ended March 31, 2016 and provided an update on its product development programs. "We are encouraged by the progress made so far this year in advancing our three clinical stage oncology drug candidates, which ...
Mar 24, 2016
SAN DIEGO, March 24, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced it will present preclinical data on two of its three oncology therapies currently in development. Data on glesatinib (MGCD265), its tyrosine kinase inhibitor targeting MET and Axl; and mocetinostat (MGCD103), its spectrum-selective HDAC inhibitor, wil...
Mar 23, 2016
SAN DIEGO, March 23, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the promotion of Jamie A. Donadio to Senior Vice President and Chief Financial Officer, effective as of March 21, 2016. Mr. Donadio first joined Mirati in 2013 serving as Vice President of Finance. In his new role, he will be responsible for a...
Mar 9, 2016
SAN DIEGO, March 9, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today reported financial results for the fourth quarter and full year ended December 31, 2015 and provided an update on its drug development programs. "We made significant progress across our entire pipeline in 2015, setting up a potentially transformative year...
Mar 8, 2016
SAN DIEGO, March 8, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Charles M. Baum, M.D., Ph.D., President and CEO of Mirati, will present a corporate overview at the Barclays Global Healthcare Conference on Tuesday, March 15, 2016 at 2:05 p.m. ET (11:05 a.m. PT) in Miami. A live audio webcast of the prese...
Jan 8, 2016
SAN DIEGO, Jan. 8, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Marcy Graham has been appointed Vice President, Investor Relations (IR) and Corporate Communications. As a seasoned communicator, Ms. Graham has more than 15 years of experience in the biopharmaceutical sector with expertise in growth companies and...
Dec 21, 2015
REDWOOD CITY, Calif. and SAN DIEGO, Dec. 21, 2015 /PRNewswire/ -- Guardant Health, the market leader in liquid biopsies, and Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX), a targeted oncology company focusing on genetic and epigenetic drivers of cancer, announced today that they have entered into a collaboration for the development of a circu...
Dec 21, 2015
CAMBRIDGE, Mass. and SAN DIEGO, Dec. 21, 2015 /PRNewswire/ -- Foundation Medicine, Inc. (NASDAQ: FMI) and Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX), a targeted oncology company focusing on genetic and epigenetic drivers of cancer, today announced that they have entered into a collaboration for the development of a companion diagnostic tes...
Dec 21, 2015
SAN DIEGO, Dec. 21, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the Phase 2 clinical trial of glesatinib (MGCD265) has commenced. The Company also announced that "glesatinib" is the proposed generic name for MGCD265. Glesatinib is an inhibitor of the MET and Axl receptor tyrosine kinase pathways which, when al...
Dec 17, 2015
SAN DIEGO, Dec. 17, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient with Non-Small Cell Lung Cancer (NSCLC) has been dosed in a Phase 1b clinical trial of MGCD516. The trial will evaluate select patients exhibiting genetic alterations in the tyrosine kinase signaling pathways, RET, DDR and Trk, w...
Dec 1, 2015
SAN DIEGO, Dec.1, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) will be presenting at the Oppenheimer 26th Annual Healthcare Conference on Tuesday, December 8, 2015 at 9:45 a.m. ET (6:45 a.m. PT) in New York. Charles M. Baum, M.D., Ph.D., president and CEO of Mirati, will provide a corporate overview. A live audio ...
Nov 6, 2015
SAN DIEGO, Nov. 6, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the third quarter ended September 30, 2015 and provided an update on its drug development programs. "Over the last quarter we made substantial progress against our goals, including strengthening our balance sheet,...
Sep 28, 2015
SAN DIEGO, Sept. 28, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX), an oncology company focusing on genetic and epigenetic drivers of cancer, today announced it presented data from the study titled, "A First-in-Human Phase 1/1b Study of Receptor Tyrosine Kinase (RTK) Inhibitor, MGCD516, in Patients with Advanced Solid Tum...
Sep 15, 2015
SAN DIEGO, Sept. 15, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the pricing of an underwritten public offering of 2,250,000 shares of its common stock at a price to the public of $45.00 per share. The gross proceeds from this offering are expected to be approximately $101.3 million, before deducting underwriting d...
Sep 14, 2015
SAN DIEGO, Sept. 14, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that it intends to offer and sell, subject to market and other conditions, approximately $80 million of shares of its common stock in an underwritten public offering. Mirati expects to grant the underwriters a 30-day option to purchase up to an additi...
Sep 11, 2015
SAN DIEGO, Sept. 11, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX), an oncology company focusing on genetic and epigenetic drivers of cancer, today announced it will present data on its tyrosine kinase inhibitor, MGCD516, at the ESMO 2015 European Cancer Congress being held in Vienna, Austria from September 25-29, 2015. ...
Sep 9, 2015
DENVER, Sept. 9, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX), an oncology company focusing on genetic and epigenetic drivers of cancer, today announced it will present data at the International Association of Lung Cancer (IASLC) 16th World Conference on Lung Cancer on the first non-small cell lung cancer (NSCLC) patient...
Aug 21, 2015
SAN DIEGO, Aug. 21, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX), an oncology company focusing on genetic and epigenetic drivers of cancer, today announced it will present data on its two tyrosine kinase inhibitors, MGCD265 and MGCD516, at the International Association of Lung Cancer (IASLC) 16th World Conference on Lung...
Aug 6, 2015
SAN DIEGO, Aug. 6, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the second quarter ended June 30, 2015 and provided an update on its drug development programs. "At this year's ASCO meeting, we presented initial clinical data on our lead tyrosine kinase inhibitor, MGCD265, whic...
Aug 5, 2015
SAN DIEGO and GAITHERSBURG, Md., Aug. 5, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX), an oncology company focusing on genetic and epigenetic drivers of cancer, and MedImmune, the global biologics research and development arm of AstraZeneca, today announced they have entered into an exclusive clinical trial collaboration...
Aug 4, 2015
SAN DIEGO, Aug. 4, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX),  a targeted oncology company focusing on genetic and epigenetic drivers of cancer, will be presenting at the 2015 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2015 at 1:55 p.m. ET (10:55 a.m. PT) in New York. Charles M. Baum, M.D., Ph.D., pr...
May 30, 2015
CHICAGO, May 30, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncolog...
May 27, 2015
SAN DIEGO, May 27, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) will be presenting at the Jefferies 2015 Global Healthcare Conference on Wednesday, June 3 at 8:00 a.m. ET (5:00 a.m. PT) in New York. Charles M. Baum, M.D., Ph.D., president and CEO of Mirati, will provide a corporate overview. A live audio webcast o...
May 13, 2015
SAN DIEGO, May 13, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today announced that the Company will provide an update on its investigational targeted tyrosine kinase inhibitor candidates, MGCD265 and MGCD516, and spectrum-selective HDAC inhibitor, mocetinostat, at the 2015 American Society of Clinical Oncology (ASCO) A...
May 6, 2015
SAN DIEGO, May 6, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the first quarter ended March 31, 2015 and provided an update on its drug development programs. "We continue to make progress across our targeted oncology clinical programs," said Charles M. Baum, M.D., Ph.D., pres...
Mar 11, 2015
SAN DIEGO, March 11, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the fourth quarter and twelve months ended December 31, 2014 and provided an update on its drug development programs. "Mirati was built on the premise that the best way to improve outcomes for patients with canc...
Feb 3, 2015
SAN DIEGO, Feb. 3, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the closing of its previously announced underwritten public offering of 2,587,500 shares of its common stock at a public offering price of $20.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 337,500...
Jan 29, 2015
SAN DIEGO, Jan. 29, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present a business overview and update at the Leerink Global Healthcare Conference on Thursday, February 12, 2015 at 8:55 a.m. Eastern Time in New York.  A live audio webcast of the presentation will be accessible on the In...
Jan 29, 2015
SAN DIEGO, Jan. 29, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the pricing of an underwritten public offering of 2,250,000 shares of its common stock, offered at a price to the public of $20.00 per share. The gross proceeds from this offering to Mirati are expected to be $45.0 million, before deducting underwritin...
Jan 28, 2015
SAN DIEGO, Jan. 28, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Mirati expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of comm...
Jan 7, 2015
SAN DIEGO, Jan. 7, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient has been dosed in a Phase 2 clinical trial designed to evaluate the efficacy, safety and pharmacokinetics of mocetinostat as a treatment for a select group of patients with bladder cancer. The trial will enroll patients whose tumo...
Jan 6, 2015
SAN DIEGO, Jan. 6, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Memorial Sloan Kettering Cancer Center in New York has dosed the first patient in an investigator-sponsored Phase 2 clinical trial of mocetinostat in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL) and follicular lympho...
Dec 23, 2014
SAN DIEGO, Dec. 23, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient with Non-Small Cell Lung Cancer (NSCLC) has been dosed in a Phase 1b clinical trial of MGCD265 in selected patients exhibiting genetic alterations of MET or Axl. In this segment of the study, one of the expansion cohorts will enr...
Nov 19, 2014
SAN DIEGO, Nov. 19, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present a business overview and update at the 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at 10:00 a.m. Eastern Time in New York.  A live audio webcast of the presentation will be accessibl...
Nov 10, 2014
SAN DIEGO, Nov. 10, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the third quarter ended September 30, 2014 and provided an update on its drug development programs. "We are excited to report that each of our clinical oncology programs are advancing and are positioned to delive...
Nov 6, 2014
SAN DIEGO, Nov. 6, 2014 /PRNewswire/ --- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that biotechnology industry veteran Michael Grey has joined its board of directors. "Mike's extensive experience in the pharmaceutical and biotechnology industries, including senior leadership and board positions in several successful companies,...
Sep 10, 2014
SAN DIEGO, Sept. 10, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present a business overview and update at BioCentury's 21st Annual NewsMakers in the Biotech Industry Conference on Friday, September 26, 2014 at 10:30 a.m. Eastern Time in New York.  A live audio webcast of the presentat...
Sep 4, 2014
SAN DIEGO, Sept. 4, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient has been dosed in its Phase 1 clinical study of MGCD516 in the treatment of patients with advanced solid tumors, with an initial focus on non-small cell lung cancer (NSCLC). MGCD516 is a Receptor Tyrosine Kinase (RTK) inhibitor w...
Aug 11, 2014
SAN DIEGO, Aug. 11, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the U.S. FDA has granted Orphan Drug Designation to mocetinostat, a spectrum selective HDAC inhibitor, for diffuse large B-cell lymphoma (DLBCL). In June, mocetinostat was granted Orphan Drug Designation as a treatment for myelodysplastic syndrome...
Aug 8, 2014
SAN DIEGO, Aug. 8, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the second quarter ended June 30, 2014 and provided an update on its drug development programs. "In the past quarter we expanded the scope of our clinical programs, identified compelling patient selection strategi...
Jun 30, 2014
SAN DIEGO, June 30, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company has been added to the Russell 2000® Index following the annual reconstitution of its U.S. and global equity indexes on June 27, 2014.   "Inclusion in the Russell Index charts a step in the rapid growth and maturation of Mir...
Jun 17, 2014
SAN DIEGO, June 17, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced that mocetinostat, the company's spectrum selective HDAC inhibitor, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration as a treatment for myelodysplastic syndrome (MDS). Mocetinostat is being developed in Phase 2 clinical studies...
Jun 12, 2014
SAN DIEGO, June 12, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 9th Annual JMP Securities Healthcare Conference on Wednesday, June 25, 2014 at 9:00 a.m. Eastern Time in New York.   A live audio webcast of the presentation will be accessible on the Investors page of the Co...
May 22, 2014
SAN DIEGO, May 22, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the Jefferies 2014 Global Healthcare Conference on June 4, 2014 at 3:30 p.m. Eastern Time in New York.   A live audio webcast of the presentation will be accessible on the Investors page of the Company's website a...
May 15, 2014
SAN DIEGO, May 15, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the first quarter ended March 31, 2014 and provided an update on drug development programs. "We are making progress in each of our development programs and we're on track to produce proof of concept data in multip...
Mar 20, 2014
SAN DIEGO, March 20, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that biotechnology industry veteran William Ringo has joined its board of directors. "Bill has excellent experience in developing and driving strategies that have enabled success for both large pharmaceutical companies and start-up biotechs. Bi...
Mar 17, 2014
SAN DIEGO, March 17, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the fourth quarter and year ended December 31, 2013 and provided a corporate update. 2013 Corporate Highlights Completed transformational corporate reorganization by recruiting highly experienced prec...
Feb 5, 2014
SAN DIEGO, Feb. 5, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 2014 Leerink Global Healthcare Conference on Thursday, February 13 at 1:00 PM Eastern Time in New York.   A live audio webcast of the presentation will be accessible on the Investors page of the Company's webs...
Dec 9, 2013
SAN DIEGO, Dec. 9, 2013 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today presented data at the 2013 American Society of Hematology (ASH) Annual Meeting demonstrating promising clinical response rates in patients with myelodysplastic syndromes (MDS) patients treated with mocetinostat in combination with azacitidine.  Separat...
Dec 2, 2013
SAN DIEGO, Dec. 2, 2013 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 25th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2013 at 10:30 AM Eastern Time in New York.   A live audio webcast of the presentation will be accessible on the Investors page of the C...
Nov 22, 2013
SAN DIEGO, Nov. 22, 2013 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 25th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2013 at 4:00 PM Eastern Time in New York.   A live audio webcast of the presentation will be accessible on the Investors page of the C...
Nov 12, 2013
SAN DIEGO, Nov. 12, 2013 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the third quarter and nine months ended September 30, 2013. Recent Corporate Highlights Completed financing that generated net proceeds of $53.0 million Strengthened our world-class precision medic...
Nov 8, 2013
SAN DIEGO, Nov. 8, 2013 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today announced that it will be presenting Phase 1/2 data on mocetinostat in myelodysplastic syndromes (MDS) at the 55th American Society of Hematology Annual Meeting taking place December 7-10 in New Orleans. Data to be presented demonstrates promising clin...
Oct 23, 2013
SAN DIEGO, Oct. 23, 2013 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 3,250,000 shares of its common stock at a price to the public of $17.50 per share.  The gross proceeds from this offering to Mirati are expected to be approximately $56.9 million, before deducting under...
Oct 16, 2013
SAN DIEGO, Oct. 16, 2013 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced that it is offering to sell 3,000,000 shares of its common stock in an underwritten public offering. Mirati also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public o...
Sep 4, 2013
SAN DIEGO, CALIFORNIA--(Marketwired - Sep 4, 2013) - Mirati Therapeutics (MRTX) today announced the appointment of Isan Chen, M.D., as chief medical and development officer as well as the appointment of Craig Johnson to its bo...
Aug 12, 2013
San Diego, California, August 12, 2013 – Mirati Therapeutics, Inc. (“Mirati”) (NASDAQ: MRTX) today reported financial results for the second quarter and first six months ended June 30, 2013. Corporate Highlights During...
Jul 19, 2013
San Diego, California, July 19, 2013 – Mirati Therapeutics, Inc. (“Mirati Therapeutics”) today announced that, consistent with its previously disclosed plans, it has applied to the Toronto Stock Exchange (“TSX”) to voluntarily delist from trading its shares of common stock.  Effective at market close on ...
Jul 15, 2013
San Diego, California, July 15, 2013 – Mirati Therapeutics Inc. (“Mirati Therapeutics” or the “Company”) today announced that the NASDAQ Capital Market (“NASDAQ”) has informed the Company that its common stock will commence trading on the NASDAQ beginning today, July 15, 2013 under the ticker symbol ...
Jun 28, 2013
San Diego, California and Montreal, Canada, June 28, 2013 –MethylGene Inc. (“MethylGene”) (TSX:MYG) and Mirati Therapeutics Inc. (“Mirati Therapeutics”) today announced the successful completion, effective June 28, 2013, of the previously announced plan of arrangement (the “Arrangement”), w...
Jun 25, 2013
Montreal, Canada, June 25, 2013 –MethylGene Inc. (“MethylGene”) (TSX:MYG) today announced that at its Annual and Special Meeting of Shareholders held in Montreal, Quebec (the “Meeting”), that over 99.99% of the votes cast by shareholders approved the previously announced plan of arrangement (the &#...
Jun 3, 2013
Montreal, Canada, June 3, 2013 – MethylGene Inc. (TSX:MYG) today announced that clinical data for mocetinostat, the spectrum selective histone deacetylase (HDAC) inhibitor, was presented at the 2013 ASCO Annual Meeting in Chicago, Illinois. Abstract #7116 – Poster – A Phase I...
May 30, 2013
Montreal, Canada, May 30, 2013 – MethylGene Inc. (TSX:MYG) today announced that Charles Baum, MD, PhD, President and Chief Executive Officer, will present an overview of the Company at the Jefferies 2013 Healthcare Conference which will be held in New York City, June 3-6 2013. The Jefferies Healthcare Conference is one of the...
May 28, 2013
Montreal, Canada, May 28, 2013 – MethylGene Inc. (TSX:MYG) today announced that clinical data for mocetinostat, the spectrum selective histone deacetylase (HDAC) inhibitor, will be presented at the 2013 ASCO Annual Meeting to be held in Chicago, Illinois from May 31st to June 4, 2013. Data will be presented from two phase II clinic...
May 13, 2013
Montreal, Canada, May 13, 2013 – MethylGene Inc. (“MethylGene” or the “Company”) (TSX: MYG) today reported financial results for the first quarter ended March 31, 2013. Corporate Highlights On May 9, 2013 we announced that subject to court approval and appro...
May 9, 2013
Montreal, Canada, May 9, 2013 – MethylGene Inc. (“MethylGene”)(TSX:MYG) today announced that its Board of Directors (the “Board”), after careful analysis, consideration and advice...
Apr 8, 2013
Montreal, Canada, April, 8, 2013 – MethylGene Inc. (TSX:MYG) today announced that preclinical data for the kinase inhibitor MG516 was presented at the American Association for Cancer Research (AACR) Annual Meeting held in Washington DC. In a poster entitled “Preclinical characteriz...
Mar 18, 2013
Montreal, Canada, March, 18, 2013 – MethylGene Inc. (TSX:MYG) today reported topline results from its human efficacy trial (Trial 290-005) with MGCD290, a novel antifungal agent targeting the fungal enzyme, Hos2.  Trial 290-005 was a randomized, multicenter, double-blind, placebo-co...
Mar 14, 2013
Montreal, Canada, March 14, 2013 – MethylGene Inc. (“MethylGene” or the “Company”) (TSX: MYG) today announced that Messrs. Jeffrey M. Besterman, PhD, Executive Vice President Research and Development and Chief Scientific Officer, Joe Walewicz, Vice President of Business and Corporate Development a...
Mar 13, 2013
Montreal, Canada.  March 13, 2013 – MethylGene Inc. (TSX: MYG) today reported financial results for the fourth quarter and full year ended December 31, 2012. Highlights On November 12, 2012, we announced the appointment of Charles M. Baum, M.D., Ph.D., as President and Chief Executive ...
Feb 19, 2013
Montreal, Canada, February 19, 2013 – MethylGene Inc. (“MethylGene” or the “Company”) (TSX: MYG) today announced that Mark J. Gergen has been appointed to the position of Executive Vice President and Chief Operations Officer, effective immediately. In this new role, Mr. Gergen will have broad responsibility for business operat...
Dec 19, 2012
Montreal, Canada, December 19, 2012 – MethylGene Inc. (TSX:MYG) today announced that it has completed enrollment in its multi-center, randomized, double-blind, placebo-controlled trial (Trial 290-005) evaluating MGCD290 plus fluconazole versus fluconazole alone in patients with moderate-to-sev...
Nov 21, 2012
Montreal, Quebec, November 21, 2012 – MethylGene Inc. (TSX:MYG) announced today it has completed its previously announced private placement of 179,690,970 units at a subscription price per unit of Cdn.$0.145 (the “Subscription Price”), each unit consisting of one common share and thirty one-hundredths (0.30) o...
Nov 14, 2012
Montreal, Canada, November 14, 2012 – MethylGene Inc. (TSX: MYG) today reported financial results for the third quarter ended September 30, 2012 and provided a corporate update. Highlights On November 12, 2012 we announced the appointment of Dr. Charles Baum M.D., Ph.D. as the Presiden...
Nov 12, 2012
Montreal, Quebec, November 12, 2012 – MethylGene Inc. (TSX:MYG) announced today its intention to complete a private placement in the United States of Cdn.$26.1 million (the “Offering”). The lead investor of the Offering is Tavistock Life Sciences (“Tavistock”), an insider of the Company, and o...
Nov 12, 2012
Montreal, Canada, November 12, 2012 – MethylGene Inc. (“MethylGene” or the “Company”) (TSX: MYG) today announced that Charles M. Baum, MD, PhD, has been appointed to the position of President and Chief Executive Officer and has joined the Company’s Board of Directors, effective immediately. Me...
Nov 8, 2012
Montreal, Canada, Thursday November 8, 2012 – MethylGene Inc. (TSX: MYG) today announced that data for the clinical-stage Met/VEGFR inhibitor MGCD265, was presented at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, in Dublin, Ireland. In the poster entitled “A Novel Assay for...
Oct 31, 2012
Montreal, Canada, Wednesday October 31, 2012 – MethylGene Inc. (TSX: MYG) today announced that preclinical data for its clinical-stage Met/VEGFR inhibitor MGCD265, will be presented at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place in Dublin, Ireland from November 6 to 9...
Oct 22, 2012
Montreal, Canada, October 22, 2012 – MethylGene Inc. (TSX: MYG) today announced that Phase I data for its novel clinical-stage antifungal, MGCD290, were presented at the 2012 IDWeek™ meeting, held in San Diego, California from October 17-21, 2012. Data describing the safety and pharmacokinetics of MGCD290 in four Phase I clini...
Oct 10, 2012
Montreal, Canada. October 10, 2012 – MethylGene Inc. (TSX:MYG) today provided a clinical update on MGCD290, the novel, orally available antifungal agent. Clinical data from four Phase I safety trials of MGCD290 will be presented at the 2012 IDWeek™ meeting, to be held in San Diego, California from October 17-21, 2012. ...
Oct 1, 2012
Montreal, Canada, October 1, 2012 – MethylGene Inc. (TSX: MYG) announced that clinical data from its MGCD265 Met/VEGFR-targeted oncology program were presented today at the European Society for Medical Oncology (ESMO) 2012 Congress, held in Vienna, Austria.  Three poster presentations provided updates on the ongoing monotherap...
Sep 24, 2012
Montréal, Canada, September 24, 2012 – MethylGene Inc. (“MethylGene” or the “Company”) (TSX: MYG) announced today that Mr. Charles Grubsztajn has left the Company as President and Chief Executive Officer effective immediately and will resign as director of the Company.  Dr. Martin Godbout, Cha...
Sep 11, 2012
Montreal, Canada. September 11, 2012 – MethylGene Inc. (TSX:MYG) today announced that preclinical data for its novel clinical-stage antifungal, MGCD290, was presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in San Francisco, California. The poster, entitled “...
Sep 4, 2012
Montreal, Canada. September 4, 2012 – MethylGene Inc. (TSX:MYG) today announced that preclinical data for its novel, clinical-stage antifungal MGCD290, will be presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place in San Francisco, California from September 9 to...
Aug 28, 2012
Montreal, Canada. August 28, 2012 – MethylGene Inc. (TSX:MYG) today announced that Mr. Charles Grubsztajn, President and Chief Executive Officer, will present an overview of the Company at the 2012 Stifel Nicolaus Healthcare Conference on Wednesday September 5, 2012 at 8:00 a.m. EDT at the Four Seasons Hotel, Boston, Massachus...
Aug 2, 2012
Montreal, Canada. August 2, 2012 – MethylGene Inc. (TSX: MYG) today reported financial results for the second quarter ended June 30, 2012 and provided an update on its clinical programs. Highlights As of August 1st, over one third of the patients have been enrolled in the first Phase II tria...
Jul 9, 2012
Montreal, Canada. July 9, 2012 – MethylGene Inc. (TSX:MYG) today announced that Mr. Charles Grubsztajn, President and Chief Executive Officer, will present an overview of the Company at the Seventh Annual JMP Securities Healthcare Conference which will be held at The Peninsula New York Hotel, New York City. Mr...
Jun 27, 2012
Montreal, Canada. June 27, 2012 – MethylGene Inc. (TSX: MYG) today announced the election of Rodney Lappe, Ph.D., to the Company’s Board of Directors at the Company’s annual meeting of shareholders held earlier today.   “Over the past year we have significantly enhanced our management team while adding four industry le...
Jun 14, 2012
Montreal, Canada. June 14, 2012 – MethylGene Inc. (TSX:MYG) today announced that Mr. Charles Grubsztajn, President and Chief Executive Officer, will present an overview of the Company at the Bloom Burton & Co. Healthcare Investor Conference which will be held at the Toronto Board of Trade on Thursday, June 21,...
Jun 4, 2012
Montreal, Canada. June 4, 2012 – MethylGene Inc. (TSX:MYG) today announced that clinical data for its Met/VEGFR multi- kinase inhibitor MGCD265 was presented in a poster session at the 2012 ASCO Annual Meeting held in Chicago, Illinois. The poster, entitled “MGCD265, a multitargeted oral tyrosine kinase recept...
May 29, 2012
Montreal, Canada. May 29, 2012 – MethylGene Inc. (TSX:MYG) today announced that clinical data for its Met/VEGF-R kinase inhibitor, MGCD265, will be presented at the 2012 ASCO Annual Meeting to be held in Chicago, Illinois from June 1 to 5, 2012. This poster presentation will highlight the safety profile of MGC...
May 23, 2012
Montreal, Canada. May 23, 2012 – MethylGene Inc. (TSX:MYG) today announced that Mr. Joseph Walewicz, Vice President, Business and Corporate Development, will present an overview of the Company at the BioFinance 2012 Conference which will be held at the St. Andrew’s Club & Conference Centre in Toronto. Mr. Walewicz will be pres...
May 14, 2012
Montreal, Canada.  May 14, 2012 – MethylGene Inc. (TSX: MYG) today reported financial results for the first quarter ended March 31, 2012 and provided an update on clinical programs.  Highlights  Rachel W. Humphrey, MD was appointed as Executive Vice President and Chief...
Apr 2, 2012
Montreal, Canada. April 2, 2012 – MethylGene Inc. (TSX:MYG) today disclosed preclinical data during a presentation for its proprietary multi-targeted kinase inhibitor, MGCD265, at the 2012 AACR Annual Meeting held in Chicago, Illinois. Results were presented showing the potent inhibition of tumor growth ...
Mar 28, 2012
Montreal, Quebec. March 28, 2012 – MethylGene Inc. (TSX:MYG) today announced that preclinical data for its multi-targeted kinase inhibitor, MGCD265, will be reported in a poster session at the 2012 American Association for Cancer Research (AACR) Annual Meeting to be held in Chicago, Illinois from March 31 to A...
Mar 19, 2012
Montreal, Quebec. March 19, 2012 – MethylGene Inc. (TSX: MYG) today announced the appointment of Peggy Mulligan, FCA to the Company’s Board of Directors. “Peggy is a financial and audit expert, and a well respected business leader. We look forward to her guidance as we plan for the future”, said Charles Grubsztajn, Pre...
Mar 15, 2012
Montreal, Quebec.  March 15, 2012 – MethylGene Inc. (TSX: MYG) today reported financial results for the fourth quarter and full year ended December 31, 2011. Highlights During the fourth quarter we commenced our first randomized, controlled Phase 2 study with MGCD290, and our two Phase 1 dose escalation ...
Feb 7, 2012
Montreal, Canada.  February 7, 2012 – MethylGene Inc. (TSX: MYG) announced today that Mr. Charles Grubsztajn, President and Chief Executive Officer, will present a corporate overview of the Company on Monday, February 13 at 4:30 p.m. EST, at the 14th Annual BIO CEO & Investor Conference. The event is being held at the Wa...
Feb 2, 2012
Montreal, Quebec. February 2, 2012 – MethylGene Inc. (TSX: MYG) is pleased to announce the appointment of Dr. Henry J. Fuchs to the Company’s Board of Directors. “Dr. Fuchs is a highly regarded leader in the biotechnology industry and brings a wealth of drug development and management experience at public life science ...
Jan 4, 2012
Montreal, Quebec. January 4, 2012 – MethylGene Inc. (TSX: MYG) today announced the appointment of Rachel Humphrey, MD, to the post of Executive Vice President and Chief Medical Officer. Dr. Humphrey is board certified in Medical Oncology and has led the development of multiple oncology agents, two of which are currently commerciali...
Page:
...
Next Last
 
= add release to Briefcase